View Older Stories View More Recent Stories

May 24, 2023 07:00AM SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 11, 2023 12:17PM SpringWorks Therapeutics (SWTX) Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at EHA
May 11, 2023 12:14PM SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 3, 2023 06:30AM SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 2, 2023 07:00AM SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 2, 2023 07:00AM SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
Apr 17, 2023 02:32PM SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
Apr 17, 2023 02:32PM BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
Apr 17, 2023 02:32PM SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
Apr 17, 2023 02:30PM MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
Apr 17, 2023 02:30PM MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
Apr 17, 2023 02:30PM MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association
Mar 8, 2023 05:05PM SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
Mar 8, 2023 05:05PM SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
Mar 1, 2023 07:00AM SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Mar 1, 2023 07:00AM SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Feb 28, 2023 06:30AM SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
Feb 28, 2023 06:30AM SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
Feb 27, 2023 06:30AM SpringWorks Therapeutics (SWTX) Announces FDA Acceptance and Priority Review of NDA for Nirogacestat
Feb 27, 2023 06:30AM SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Feb 27, 2023 06:30AM SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Jan 9, 2023 06:34AM SpringWorks Therapeutics (SWTX) Highlights Anticipated Milestones for 2023
Jan 9, 2023 06:30AM SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
Jan 9, 2023 06:30AM SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 07:00AM SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 07:00AM SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 27, 2022 06:32AM SpringWorks Therapeutics (SWTX) Completes NDA Submission for Nirogacestat
Dec 27, 2022 06:30AM SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Dec 27, 2022 06:30AM SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Nov 22, 2022 07:00AM SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
Nov 22, 2022 07:00AM SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
Nov 3, 2022 06:30AM SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 3, 2022 06:30AM SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Sep 29, 2022 06:32AM SpringWorks Therapeutics Inc. (SWTX) Doses First Patient in Phase 2 Trial of Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Sep 29, 2022 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Sep 29, 2022 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Sep 12, 2022 05:43AM SpringWorks Therapeutics (SWTX) Reports Additional Phase 3 DeFi Trial Data
Sep 10, 2022 10:30AM SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2
Sep 10, 2022 10:30AM SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2
Sep 7, 2022 09:57AM SpringWorks Therapeutics (SWTX) Announces $225 Million Private Placement Financing
Sep 7, 2022 09:56AM SpringWorks Therapeutics Announces $225 Million Private Placement Financing
Sep 7, 2022 09:56AM SpringWorks Therapeutics Announces $225 Million Private Placement Financing
Sep 7, 2022 09:55AM SpringWorks Therapeutics (SWTX) Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Sep 7, 2022 09:55AM SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Sep 7, 2022 09:55AM SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Aug 19, 2022 06:30AM SpringWorks Therapeutics Inc. (SWTX) Reports Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
Aug 19, 2022 06:30AM SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
Aug 19, 2022 06:30AM SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
Aug 4, 2022 06:30AM SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Aug 4, 2022 06:30AM SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
View More Recent Stories View Older Stories